Oleg Nodelman
Chief Executive Officer at PANACEA ACQUISITION CORP. II
Profile
Mr. Oleg Nodelman is an Independent Director at AnaptysBio, Inc., a Chairman & Chief Executive Officer at Panacea Acquisition Corp.
II, an Independent Director at Prothena Corp.
Plc, a Founder & Portfolio Manager at EcoR1 Capital, LLC and a Chief Executive Officer at EcoR1 Panacea Holdings LLC.
He is on the Board of Directors at AnaptysBio, Inc., Prothena Corp.
Plc, Aktis Oncology, Inc., Paratus Sciences Corp., ReCode Therapeutics, Inc. and Scorpion Therapeutics, Inc. Mr. Nodelman was previously employed as an Independent Director by Nuvation Bio, Inc., a Chairman & Chief Executive Officer by Panacea Acquisition Corp., a Non-Executive Director by Addex Therapeutics Ltd., a Portfolio Manager by Biotechnology Value Fund LP, and a Portfolio Manager by BVF Partners LP.
He received his undergraduate degree from Georgetown University.
Oleg Nodelman active positions
| Companies | Position | Start |
|---|---|---|
| PROTHENA CORPORATION PLC | Director/Board Member | 2019-12-02 |
| PANACEA ACQUISITION CORP. II | Chief Executive Officer | 2020-12-31 |
| ANAPTYSBIO, INC. | Director/Board Member | 2021-04-07 |
EcoR1 Capital, LLC
 EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | Chief Executive Officer | 2011-12-31 |
| EcoR1 Panacea Holdings LLC | Chief Executive Officer | - |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Director/Board Member | - |
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Director/Board Member | - |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Director/Board Member | - |
Paratus Sciences Corp.
 Paratus Sciences Corp. BiotechnologyHealth Technology Paratus Sciences Corp. is an American company that focuses on unlocking the secrets of bat biology. The company's main goal is to elucidate novel insights and identify new therapeutic targets. The company was founded by Thomas Zwaka, Richard Young, Paul Matsudaira. The CEO is Amir H. Nashat. | Director/Board Member | - |
Former positions of Oleg Nodelman
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░ ░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Oleg Nodelman
| Georgetown University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ANAPTYSBIO, INC. | Health Technology |
| ADDEX THERAPEUTICS LTD | Health Technology |
| PROTHENA CORPORATION PLC | Health Technology |
| NUVATION BIO INC. | Health Technology |
| Private companies | 10 |
|---|---|
Biotechnology Value Fund LP
 Biotechnology Value Fund LP Investment ManagersFinance Part of BVF, Inc., Biotechnology Value Fund LP is an Alternative Investment Manager. The private company is based in San Francisco, CA. | Finance |
BVF Partners LP
 BVF Partners LP Investment ManagersFinance BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts. | Finance |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | Finance |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Technology |
Panacea Acquisition Corp.
 Panacea Acquisition Corp. Financial ConglomeratesFinance Panacea Acquisition Corp. is a blank check company with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in April 2020 and is headquartered in San Francisco, CA. | Finance |
| EcoR1 Panacea Holdings LLC | |
Panacea Acquisition Corp. II
 Panacea Acquisition Corp. II Financial ConglomeratesFinance Panacea Acquisition Corp. II operates as a blank check company. It seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 14, 2021 and is headquartered in San Francisco, CA. | Finance |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Health Services |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Paratus Sciences Corp. is an American company that focuses on unlocking the secrets of bat biology. The company's main goal is to elucidate novel insights and identify new therapeutic targets. The company was founded by Thomas Zwaka, Richard Young, Paul Matsudaira. The CEO is Amir H. Nashat. | Health Technology |
- Stock Market
- Insiders
- Oleg Nodelman
